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Prognostic value of HCV genotype in HIV-HCV 
co-infected patients 
L. Piroth', C. Bourgeois', S. Dantin', A. Waldner', M.  Grappin', 
H. Portier', P. Chavanet'. 'Inffaious Diseases Department, zVirolqy, 
CHU Dijon, -'Rorhe Laburatories, Nwilly-rur-Sertre, Fratw 
Objectives: To assess the prognostic value of HCV genotype on 
clinical and immunologic evolution of HIV-HCV co-infected 
patients 
Methods: One hundred and sixteen HIV-HCV co-infected 
patients enrolled in a historical cohort were longitudinallj~ studied. 
Results: Thirteen patients (22.4%) met C D C  criteria for CMV 
disease diagnosis (CDD). Assays pp65Ag pp65Ag CMVQual CMM 
threshold (0+ cells) (5+ cells) (400 ceUs/mL) Se 92.3 92.3 76.9 84.6 
Sp 93.3 100.0 100.0 100.0 PPV 80.0 100.0 100.0 100.0 NPV 97.7 
97.8 93.8 95.7 Ist+sample 124 74 46 46 pi-ior to C D D  (days) At 124 
days before CDD, pp65Ag Se, pp65Ag Sp, PPV and NPV were 
respectively 6094, 94%, 60% and 94%. At 46 days, these values were 
54%, loo%, 100% and 91% for CMVQual, and 57%, 97%, 80% and 
91% for CMM. At CDD, median CMV load was 9070 copies/mL 
and became <400 after 8 weeks with therapy 
Conclusions: The CMM assay detects CMV disease with 
interesting Se and Sp within 46 days before CIIII, which is coni- 
patible with clinical follow-up. This suggests that plasma CMV IINA 
is a valuable decision marker for initiating pre-emptive therapy. 
ml Rationale for a hospital-based pneumococcal Blood sainples were prospectively collected at first visit and thereafter 
every 3 months. HCV R N A  was detected by PCK and then a 
genotype determination was performed. Clinical progression was 
defined as one or more of the following: a 30% decrease of the 
Karnofsky's index, a 20% loss of body weight, an AIDS-defining 
illness (for non-AIDS patients), or death (except by accident, suicide, 
overdose). Immunologic progression was defined as a 50% decrease 
of the initial CD4 T-cell count. Effects of HCV genotype were 
vaccine strategy for HIV-infected South 
Africans 
G..Genovese', R.A. Siiiego J?. 'University $the 
W i t i u a t e r s r a n d / S A I ,  Jookannrsbiq, Soirrlr Africa; 2LJrriurrsity ($ 
Wstmirrster, London, UK 
- .. 
evaluated using Kaplan-Meier survival analysis and significance was We explored the rationale for a hospital-based piieiiniococcal vaccine 
tested using univariate (log-rank test) and multivariate (Cox's model) strategy by retrospectively examining the medical records of 104 
methods patients with Sfreptomrcus pneumoniar isolated from blood (88 
Results: Twenty-four (20.7%) co-infected patients had undetect- patients), cerebrospinal fluid (five patients), or both (six pat lent^) 
able HCV RNA. and only five (4.2%) had detectable HCV R N A  fronil January 1997 to 31 December 1997. Where HIV status was 
but undetermined genotype (because of low HCV R N A  levels). known, 92% were HIV seropositive. O f  the 70 persons 2 years ofage, 
Genotype 1 was found in 49 (42.2%) patients, subtype l a  in 28 20 (29%) had been hospitalized at least once during the previous 4 
(24.1%), and cubtype b in 13 (11.2%); eight (6.9%) were non-la years. HIV status was known by patients before (62'%1), during (30'%), 
non-lb. Genotypes 3, 4 and 2 were observed in 25 (21.6%), 11 and after (8%) hospitalization for pneumococcal infection. Only three 
(9.5%) and two (1.7%) patients, respectively. According to HCV of 53 (6%) HIV-seropositive patient5 2 years of age had CD4+ cell 
genotype, clinical and immunologic evolution were not significantly counts known before pneumococcal hospitalization, indicating poor 
different in univariate analysis (p=O. 10 and p=0.29, chi-squared HIV clinic enrollment. Only 47 of the 104 (45%) pneumococcal 
tect). In multivariate analysis, initial CD4 T-cell count, initial isolates belonged to serotypes contained in the 23-polyvalent 
Karnofsky's index and initial clinical status were significant prognostic pneumococcal vaccine. In-hospital, pre-discharge HIV testing and 
factors of clinical and immunologic evolution, whereas HCV pneumococcal vaccination, perhaps combined with outpatient HIV 
genotype was not ( p 4 . 9 5  and p=0.63)  site testing vaccination, is an underutilized but potentially cost- 
Conclusions: HCV genotype does not appear to be an important effective preventive measure for HIV patients. In our province and 
prognostic factor for HIV-HCV co-infected patients'clinical and in other areas with a high frequency of disease caused by serotypes 
immunologic evolution not contained in the vaccine, the utility of immunization could be 
limited. 
vl Prognostic value of CMV plasma load in AIDS 
patients using pp65 antigenemia, AMPLICOR 
CMV and a new quantitative test: COBAS 
AMPLICOR CMV MONITOR 
G. Pellegrin, C. Binquet, I. Garripe, G. Chene, HJ.A. Fleury, 
J.-L. Pellegrin. CHU Pellegtin, Lahoratuire de virologie, Bordeaux, Frame 
Objectives: To assess the performance of CMV pp65 antigenemia 
(pp65Ag), AMPLICOK CMV (CMVQual, Roche) and the new 
COBAS AMPLICOR CMV MONITOR (CMM, Koche) assay for 
diagnosis and follow-up of CMV disease in AIDS patients 
Methods: Fifty-eight AIDS patients (< 100 LTCD4+/pL) were 
enrolled between November 1995 and September 1997 and followed 
up every 2 months with pp65Ag, CMVQual and CMM 
I 0 4  I Analysis of HIV genotype in patients 
experiencing a rebound in viral load on 
efavirenz (EW, SUSTIVA, DMP 266) plus 
nelfinavir (NW) combination therapy 
(DMP 266-024) 
E.D. Anton, L.T. Bacheler, DJ. Manion, IhPont  Pharniaceutical5 
Company, Drpt .  if Viroloqy, Wilminyton, USA 
Background: DMP 266-024 is a 48-week, open-label, cingle-arm 
study enrolling 30 antiretroviral naive and 32 nuc leode  analog 
reverse transcriptase inhibitor (NRTI) experienced HIV-1 -infected 
patients. EFV plus NFV were administcred and all other antiretroviral 
agents were discontinued 
53 
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Objective: To identify HIV resistance mutations associated with 
a rebound in viral load in patients receiving EFV plus NFV con-  
bination therapy 
Methods: Population-based DNA sequencing was performed on  
the RT-PCR product derived from patient plasma samples collected 
at baseline and at the first time point after viral rebound with HIV 
RNA 1000 copies/mL. A 1650-bp region was sequenced, including 
the p7/pl and pl /p6 protease cleavage sites, the protease gene (PR), 
and the first 350 amino acids of the reverse transcriptase gene (RT) 
Results: To date, 17 (SIX naive and 11 NRTI experienced) patients 
have failed EFV plus NFV combination therapy. We have genotypic 
data corresponding to the initial rebound in viral load for 10 of these 
patients. Eight developed a K103N RT mutation and two acquired 
an additional RT mutation: either LlOOI or KlOlQ. Two patients 
had an RT mutation at G190: one G-E and one G-S. Two patients 
developed the NFV P R  resistance mutation D30N and one each 
acquired D60E or M36I. N o  changes were observed in the p7/pl 
cleavage site: one patient showed a P-T change in the P5 
1x1 Nelfinavir (NFV)/saquinavir (SQV) plasma drug 
levels in two different dosage schedules: a 
pilot study 
D. Dalmau, 1. Gbmez, X. Martinez-Lacasa, M. Cervantes, 
H.  Knobel, P. Domingo, J. Garau. Hospitaf Mnfna de %rrassa, 
Infctious Diseases Unit, Terrassa, Spain 
Background: Several studies have attempted to demonstrate 
different therapeutic options for patients with advanced HIV in- 
fection failing primary triple therapy with two nucleoside reverse- 
transcriptase inhibitors (NRTIs) and a potent protease inhibitor (PI); 
however, the ideal dosages of new combinations (1.e. NFV/SQV) 
remain to be established 
Objective: To assess the different plasma drug concentrations and 
tolerances of two different b.i.d. schedules prior to initiating salvage 
therapy in NtW/SQV-naive patients 
Methods: An open-label study was performed in patients treated 
with two different combination regimens of NFV/HGC-SQV (1) 
NFV, 1250 mg b.i.d.+SQV, 800 ing b i d . ;  (2) NFV, 1250 mg 
b.i.d. +SQV, 1000 mg b.i.d. Plasma concentrations were analyzed 
with a vahdated HPLC assay in five and six patients in each dosage 
schedule (regimens A and B respectively), after at least 1 month of 
NFV/SQV therapy 
Results: NFV (ng/mL) SQV (ng/mL) Mean2SD Range Mean 
rtSD Range Regimen A (trough) 299922529 1172-7344 4252 623 
61-1527 Regimen B (peak) 7056+5751 3253-17213 15342783 
510-2571 Regimen B (trough) 307321735 1621-5741 827k983 
231-2562 lCrs for NFV 40 ng/mL ICW for SQV 39 ng/mL All 
patients included in the study had a good tolerance 
Conclusions: Both dosage schedules exceeded by far ICUO and 
C,,,,, parameters during the whole dosing interval. Assuming a good 
tolerance in both regimens, it remains to be seen if the superior SQV 
trough levels of regimen B have a more intense and sustained effect 
in viral load and CD4 cell counts. 
wl A phase II, open-label, multicenter study to 
characterize the effectiveness and safety of 
efavirenz (EFV) in combination with stavudine 
(d4T) and lamivudine (3TC) in antiretroviral- 
naive HIV-infected patients (study 
DMP 266-043) 
C. Cohen’, R. Elion’ , S. Green? , M.E. Eyster‘ , D.E Labriola’, 
D.J. Manion’, S.L. Boyko’, N.M. Ruiz’, The Study 043 
Investigator Team. ‘Community Research Initiative of New England, 
Boston, MA, Washington, DC, ’Hampton Road Medical Specialists, 
Hampton, C:4, ‘The Miltori S. Hershey Medical Center, Hershey, PA, 
’DuPonf Pliannaceuticals Company, it’ilmington, DE,  USA 
EFV (SUSTIVA) is a once-daily NNRTI that has demonstrated equal 
to superior efficacy and superior tolerability to protease inhibitor- 
containing standard-of-care regimens when used with AZT and 3TC 
(Study 006,36 weeks). We sought to further explore the effectiveness 
of EFV and NRTIs, by combining it with d4T and 3TC, an 
increasingly popular NRTI combination 
Objectives: To assess the safety and effectiveness of EFV in 
combination with d4T and 3TC in antiretroviral (ARV)-naive, HIV- 
infected patients 
Design: This is a 48-week, open-label, multicenter study 
Inclusion criteria: ARV-naive, baseline plasma HIV RNAlO 000 
copies/mL. There was no CD4 cell count limit. ALl patients were to 
receive EFV (600 mg q.d.), d4T ( 3 W 0  mg q12h) and 3TC (150 mg 
Preliminary demographics: 92% male; 44% Caucasian; 52% 
Black: mean age 36.426.6 years; mean baseline loglo plasma HIV 
R N A  4.8420.62 copies/mL (geometric mean 69 183 copies/mL); 
mean baseline CD4 count 3862287 cells/mm 
Methodology: Three methods of analysis were performed 
observed data (OBS, ‘on-treatment’ analysis); intent-to-treat (1TT)- 
last observation carried forward (LOCF, missing values values im- 
puted as last available for that patient); and ITT-non-completer 
equals failure (NC=F, dropouts and missing data imputed as failure 
(unless bordered by successes, in which case data for that patient were 
censored)) 
Results: At the time of submission, all 60 patients had been 
enrolled in this study. Full 16-week safety and efficacy results will be 
available at the time of presentation. Preliminary safety results indicate 
that the combination of efavirenz plus d4T and 3TC is generally well 
tolerated 
q12h) 
ml A phase 111, double-blind, placebo-controlled, 
multicenter study to determine the 
effectiveness and tolerability of the 
combination of efavirenz (EFV, SUSTIVA TM, 
DMP 266) and indinavir (IDV) versus IDV in 
HIV-1 -infected patients receiving nucleoside 
analogue therapy (NRTI) at 24 weeks (study 
DMP 266-020) 
D.W. Haas’, W.J. FesseI*, R.A. Delapenha’, H. Kessler4, DJ. 
Manion’, L. Ploughman’, R. Croop’, N.M. Ruiz5, D.E Labriola’, 
The Study 020 Investigator Team. ’ knderbilr University, Nashville, 
TN, *Kaiser Permarrente, San Francisco, CA, ’Howard University, 
Wkqhington, DC,  4Chicap Centerfor Cfinicuf Reseurch, Chicago, It, 
5Clinical Research and Deuelopment, DwPonr Pliarmaceuticafs Company, 
it’ilmington, D E ,  USA 
EFV is a once-daily NNRTI 
enrolling 331 patients 
Study design: Placebo-controlled (to 24 weeks), randomized, 
A b s t r a c t s  55 
Inclusion criteria: NKTI-experienced (=8 weeks), PI-, 
NNRTI-naive; baseline HIV-1 RNA = 10 000 cps/niL; baseline 
CD4 count=50 cella/miii'. Patients received maintained or changed 
NRTI plus either placebo (PL13) IDV (800 nig q8h) or EFV (600 mg 
q.d.) IDV (1 000 nig q8h). Baseline: 83% niale; 53% Caucasian; age 
38.9+-8.2 years; logit, HIV-1 KNA 4.3920.57 copies/niL; CD4 cell 
w] Analysis of CTL escape in a cohort of 
HIV-positive patients 
M. Bsuerle, M. Schmitt, A. Goldwich, E. Harrer, P. L ~ w ,  
1. Graedner, J.R. Kalden, T. Harrer. Uriiversify Erlan,~c~ri-~nrenihr.ry,  
Mrd. Inst. 111, Erlaii.yeri, Germany 
count 330.1 2 165.9 celIs/inrir3 
Preliminary results: Sixty-eight per cent changed NRTIs. 
Responder rates: percentage <400 cps/mL--84%, 69% and 59% of 
patients treated with EFV IDV NRTIs versus 66%, 52% and 50% for 
IDV NRTIs responded (observed, I T T  LOCF; I T T  NC=F); 
percentage <50 copies/mL (Ultrasensitive Assay)-69'%, 49% and 
49% of patients treated with EFV IDV NRTIs versus 4796, 36% and 
36% treated with IIlV NRTls responded. EFV IDV NRTIs were 
statistically superior to ILlV NRTIs in all analyses save ITT NC=F% 
==400 cps/niL. Mean CD4 counts increased by 104 and 93 
cells/min' on EFV IDV NRTIs and IDV NRTIs, respectively. The 
EFV regimen was generally well tolerated. More patients had new- 
onset skin rashes and nervous system symptoms on the EFV- 
containing regimen, but these were mild or moderate in severity; 
none were grade 4, and few patients required dose adjustnieiit or 
discontinuation from the study 
Conclusions: In RTI-experienced patients, EFV IDV and one or 
two NRTIs (new or maintained) demonstrated superior efficacy 
compared to PLB IIlV and one or two NRTls at 24 weeks. These 
results at 2 1  weeks arc supportive of the results of study ACTG 364 
reported previously 
w] Undetectable viral load achieved by different 
antiretroviral regimens 
J.M. Guardiola, E Madrid, E. Negredo, P. Doiningo, J. Ris, 
M.Gurgui, M.A. Sambeat, J. Cadafalch, M. Fuste, G.Vazquez 
Iriternal Mediriiitz, Hospital Sanf Pau, Barcrloria, Spairi 
Four groups of patients receiving different regimens of antiretroviral 
therapy were analyzed aher a follow-up of 18 inoiiths In terins of 
percentage of undetectable viral load (<200 copies/mL). Statistical 
analysis was performed using the chi-square test and Fisher exact test. 
Two hundred and sixty-one patients were included and classified into 
four groups. The first group consisted of those patients receiving 
double therapy (DT) (n=SO); the second group consisted of patients 
naive to any previous aiitiretroviral treatment receiving HAART 
(NVE) (n=27); the third group consisted of those antiretrovira- 
experienced patients receiving HAART (EXP) (n=118); and the last 
group included those patients who began HAART and had to change 
at least two drugs (CT) (n=66). An equivalent level of compliance 
was observed. Mean age was 38.7 ? 6.2 years (range 21-74), and 
57.2% were men. Mean time since HIV infection was 6.7+-3.1 (range 
1-15), Mean time since antiretroviral treatment at time of inclusion 
was 28.4?21.7 months (range 1-87), except for the W E  group. 
Basal viral load was 5.625.5 log (0-6.7 logs). Basal CD4 count was 
225'286/nmi' (range 13-826). N o  differences between groups were 
found except for the basal CD4 count (iiiean=460;p=0.04) in group 
DT. Percentages of undetectable viral load are as follows: 29/50 
(58%), 24/27 (89%) 75/118 (63.5%) and 44/66 (66.6%) for the 
groups DT, NVE, EXP and CT respectively (p=0.045). NVE was 
differerent to the rest (NVE versus DT, p=0.005; NVE versus EXP, 
p = O . O l ;  NVE versus CT, p=0.038) 
Conclusions: In our series, the highest percentage of patients 
with undetectable viral load was achieved in the naive group (NVE) 
Objective: To study the influence of CTL escape on the course of 
HIV-1 infection in a cohort of HIV-I-infected patients 
Methods: We studied in 32 HIV-1 -positive patients sequence 
variation in three HLA A2 restricted HIV-1 -specific CTL epitopes: 
SLYNTVATL (p17-SL9), VIYQYMDDL (RT-VL9) arid 
ILKEPVHGV (RT-IV9). Autologous viruses from PHA-stimulated 
PBMCs were analyzed by nequencing of PCX-aiiiplified proviral 
HIV-1 DNA. Recognition of viral variants was tested by using 
peptides and CTL lines from HIV-1-infected paticnts. I n  addition, 
we aiialyzed PBMCs for the presence of CTL with the ELISPOT 
assay 
Results: So far, we have detected mutations in the RT-lV9 
epitope in eight of 27 patients, in the RT-VL9 epitope in 14 of 32 
and in the pl7-SL9 epitope in 15 of 29. In the RT-VL'I epitopc, the 
amino acid substitutions within the epicope correnpond in seven of 
the 14 patients to defined drug resistance mutations. Whereas niuta- 
tions in the SL9 epitope are already frequently observed in  early stages 
of infection, mutations iii the 1V-9 epitope are predominaiitly found 
in advanced patients. The majority of inutations studied so far can 
decrease recognition by specific CTL lines. However, the capacity for 
immune escape of specific mutations varies strongly between 
individual CTL lines 
Conclusions: We detected a significant degree of sequence 
variation in conserved CTL epitopec. The majority of mutations 
decrease CTL recobmition. At least in a subset of patients, CTL cscape 
seems to play an important role in the pathogenesis of HIV-1 
infection 
m] Hypertriglyceridemia in patients with HIV 
disease: frequency and role of antiretroviral 
treatment 
R. Manfredi, M. Llorderi, S.Talh, S. Spinosa, M.Tadolini, 
C,  Donzelli, E Chiodo. Department of Clinical arid Experirnerital 
Medirine, Uriiiwrsity qf Bolopa, Italy 
Objective: To assess the frequency of hypertriglyceridemia (HT) 
during HIV disease, and its relationship with antiretroviral treatment 
Methods: Forty patients treated with ritonavir (RTV), 40 
receiving indinavir (IDV), 40 treated with reverse transcriptate 
inhibitors (KTIs) only, and 40 who did not receive (or refused) 
antiretrovirals, were randomly celected anioiig -1 000 HIV-infectcd 
patients followed by us, provided that they had four coiisecutive 
laboratory evaluations carried out every 3 months, while on the 
relevant medication, since 3 months of H T  was defined by planma 
triglyceride levels of 172 mg/dL 
Results: Our four patient groups were comparable as to 
demographic features (data not shown), underlying iinmuno- 
deficiency (mean CI14+ lymphocyte count), and duration of therapy 
with either RTV, DV, or RTI. Fifty-one patients of 160 (31 .Y%) had 
at least one positive result for H T  during their follow-up, but sign- 
ficant differences were seen between patients treated with KTV or 
IDV, and those receiving RTI or no therapy, as to occurrence of H T  
(p<0.001, chi-square test), and inean and peak plasnia triglyceride 
levels (p<O.O01, Student t-test). Compared with the lI1V group, the 
RTV group included a significantly greater number of patients 
developing HT @<O.OOl) ,  and showed much higher mean and peak 
plasma triglyceride values @<0.001), with levels > 1500 mg/dL 
56 Cl in ica l  M i c r o b i o l o g y  and In fec t ion ,  Vo lume 5 Supp lement  3 
being reached in five patients after 6.2-tl.8 months. No clinical 
disturbances attributable to HT were seen, but in 12 patients anti- 
lipemic agents were introduced, and six patients interrupted their 
treatment due to persistently elevated HT 
Conclusion: HT is increasingly recognized among HIV-infected 
patients, but its frequency and severity appear to be strictly related to 
anti-HIV therapy carried out with some protease inhibitors. Careful 
monitoring of plasma triglyceride levels is mandatory for patients 
treated with RTV 
Endocarditis and Sepsis 
1x1 Two hundred and twelve cases of infective 
endocarditis in central Europe: predictors of 
outcome 
R.O.M. Netzer, E. Zollinger, C. Seiler, A. Cerny Inselspital, Ab t .  
Innere Medirin, Berne, Switzerland 
Objective: The present study sought to determine variables 
associated with the outcome ofinfective endocarditis (IE) at a tertiary 
referral center 
Methods: In a restrospective chart review, all 212 patients who 
fulfilled the Duke criteria for IE between 1 January 1989 and 31 
December 1995 were included and followed until death or discharge. 
Demographic, clinical and echocardiographic factors were examined 
regarding their association with outcome 
Results: Comparing the periods 198&87 and 1988-95, the 
clinical presentation, microbiology and mortality (16% versus 14%. 
respectively) have remained unchanged. Also, other endpoints, such 
as cerebral deficit and cerebral hemorrhage, as well as the requirement 
for valve surgery, were not significantly different between the two 
periods studied. Multivariate analysis revealed the presence of 
neurologic symptoms at presentation as well as arthralgia and weight 
loss to be independent risk factors for mortality (odds ratios, 26.1, 
6.2 and 4.2, respectively) 
Conclusion: Despite the introduction of new imaging tech- 
niques, the clinical presentation and outcome of patients with IE has 
remained remarkably stable between 1980 and 1995. Clinical findings 
suggestive of systemic involvement were found to be independent 
predictors of death; importantly, age was not. Taken together, our 
results indicate that early aggressive treatment of IE is mandatory in 
all age groups. 
10121 Et’ rology and risk factors of 180 cases of native 
valve endocarditis: report from a National 
Prospective Survey in the Slovak Republic 
Vasil Hricak’, Juraj Kovacik’, V Krcmer?, the Slovak Endocarditis 
Study Group. ‘National Institute of Cardiovascular Disease, ’Clinic of 
Infectious Diseases, Bratislava, Wniversity of Tunava, School of Public 
Health, Slovak Republic 
Risk factors, etiology and outcome of 180 cases of infective endo- 
carditis (IE) in the Slovak Republic within 5 years were prospectively 
studied in a national survey. According to the Duke Endocarditis 
Service Criteria, 169 cases were considered definitive and 21 
possible/probable. The aortic valve was infected in 46.796, the mitral 
valve in 47.2% and the tricuspidal/pulmonary valve in 6.1% of cases. 
The majority of endocarditis cases were caused by staphylococci 
(33.3%), only 12.2% being due to viridans streptococci, 11.7% to 
Enferococcusfaecalis, and 6.1% to the HACEK group; 26.7% were 
culture negative. Cases of staphylococcal and corynebacterial endo- 
carditis with single positive culture were not considered as clinically 
significant. Univariate analysis comparing deaths and survivors did 
not show significant differences in most of the recorded risk factors 
between both groups, except for age 60 (40.0% versus 21.4%, 
P<0.05), staphylococcal etiology (55.0% versus 27.1%, P <0.04) and 
antibiotic therapy 1 2 1  days (without surgery) (65.0% versus 3.6%. 
D-0.01) which were significantly more frequently associated with 
deaths in comparison to survivors. Viridans streptococcal infectious 
endocarditis and surgical therapy in addition to antibiotics were 
associated with lower mortality in comparison to staphylococcal 
endocarditis (P<0.045) or to cases treated with antibiotics only 
(W0.05) 
m] Catheter-related sepsis: an easy method of 
diagnosis? 
P. Honderlick, P. Cahen. Ilficrobiologie, Hopital Foch, Suresnes, France 
Over an 18-month period we retrospectively compared clinical diag- 
nosis of catheter-related sepsis to the speed of detection of catheter 
versus peripheral blood cultures (using the Bact-Alert system, 
Organon Teknika). Usually, when catheter infection is suspected, to 
prove it, quantitative cultures from blood drawn simultaneously from 
the catheter and the peripheral vein (Isolator-Dupont de Nemours) 
and quantitative culture of the catheter when removed are realized. 
The aim of the study was to determine if the uncertain and difficult 
diagnosis of catheter-related sepsis may be improved without 
removing the catheter. Only the first pair of blood cultures was 
considered for analysis. Forty-five patients with indwelling devices 
were analyzed: 17 were classified as infected; differential time of 
detection of catheter blood culture correctly identified 15 infections. 
On the other hand, using standard diagnostic methods, 28 catheters 
were estimated to be non-infected; in 24 cases we observed equal or 
a more rapid speed of detection of peripheral blood culture. Four 
discrepancies are recorded with an earlier positivity of catheter blood 
ranging from 0.5 to 2. A cut-off limit of 1 h had a sensitivity of88.2% 
and a specificity of 85.7%. The positive and negative predictive values 
are, respectively, 78.9% and 92.3%. This method could be the first 
step of diagnosis of catheter-related bloodstream infection, especially 
in cases in which the catheter is not withdrawn for culture 
IL-Ira and IL-6 allow diagnosis of neonatal 
sepsis 2 days before clinical manifestation 
A. Willeitner, H. Kuster, M. WeiB, G. Simbruner. Kinderpoliklinik 
und Kinderklinik der Universitdt, Dr von Haunersches Kinderspital, 
Munich, Germany 
Objectives: To determine the prognostic power of plasma levels of 
the cytokines interleukin-1 receptor antagonist (IL-lra) and inter- 
leukin-6 (IL-6) for early diagnosis of neonatal sepsis, as compared to 
clinical signs of infection and the conventional marker CRP 
Methods: In a prospective multicenter study we investigated the 
time course of expression of IL-lra, IL-6 and CRP before clinical 
diagnosis of sepsis in 182 very low birthweight (VLBW) infants 
Results: In 28 cases of culture-proven neonatal sepsis, IL-lra and 
IL-6 increased significantly 2 days prior to clinical diagnosis of sepsis 
as compared to baseline values measured in the absence of sepsis. 
Median increases were 15-fold for IL-lra and 12-fold for IL-6. 
Sensitivities for IL-lra, IL-6 and CRP levels on the day of clinical 
diagnosis were 93%, 86% and 43%. Sensitivities 1 day prior to 
diagnosis of sepsis were 64%. 57% and 18% respectively Specificities 
were 92%, 83% and 93% 
